ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer

Business Overview EPIX is a clinical-stage pharmaceutical company focused on developing therapies for prostate cancer. It was founded in 2009 and operates in Houston, San Francisco, and Vancouver. Today, EPIX's science focuses on therapies designed to disrupt the androgen receptor [AR] using N-terminal Domain [NTD] inhibitors called Anitens to inhibit cancer growth. Prostate cancer is the most common cancer in men in the U.S. and the second cause of male cancer deaths. About 1 in 8 men will be diagnosed wit ...